Jagsonpal concludes ₹40 crore buyback at ₹250 per share

Jagsonpal Pharmaceuticals Limited has successfully concluded its buyback process, which closed on May 14, 2026. The company bought back 16,00,000 fully paid-up equity shares, representing 2.39% of the total outstanding shares as on the record date of May 4, 2026. The buyback was executed through the Tender Offer route at a price of ₹250 per equity share, aggregating to a total consideration of ₹40,00,00,000, excluding transaction costs.

Buyback Details and Subscription

The offer received significant interest from shareholders, with the Registrar to the Buyback receiving 4,429 valid applications for 58,73,380 equity shares. This resulted in a subscription level of approximately 3.67 times the maximum number of shares proposed to be bought back. The acceptance ratio varied across categories, with the General Category for other Shareholders seeing a higher subscription rate compared to the Reserved Category for Small Shareholders.

Category of Shareholders	No. of Equity Shares reserved	No. of valid applications	Total Equity Shares Validly Tendered	Times Subscription
Reserved Category for Small Shareholders	2,40,975	3,932	6,40,435	2.66
General Category for other Shareholders	13,59,025	497	52,32,945	3.85
Total	16,00,000	4,429	58,73,380	3.67

Settlement and Capital Structure

The settlement of valid bids was completed by the Clearing Corporations on May 21, 2026, with funds directly paid out to eligible shareholders. Equity shares accepted under the buyback were transferred to the company's Demat Escrow Account on the same day. Consequently, the extinguishment of the 16,00,000 accepted shares is currently under process and is expected to be completed on or before June 2, 2026.

Post-buyback, the company's issued and subscribed paid-up capital stands at 6,55,39,150 equity shares of ₹2 each, amounting to ₹13,10,78,300. The promoter and promoter group holding has increased to 69.36% of the post-buyback equity share capital.

Major Shareholders

A significant portion of the buyback was accounted for by major shareholders. Entities holding more than 1% of the total equity shares bought back included Authum Investment And Infrastructure Limited, Manish Gupta, and Ashoka India Equity Investment Trust Plc. Collectively, the top nine shareholders accounted for 54.03% of the total equity shares bought back under the offer.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.12%	-2.84%	-3.98%	-7.23%	-14.79%	+294.05%

Jagsonpal Pharmaceuticals Limited has informed the stock exchanges of the resignation of Mrs. Pallavi Dinodia Gupta (DIN- 06566637) from the position of Independent Director of the company, with effect from May 18, 2026. The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule III of the Listing Regulations.

Resignation Details

The company intimated the exchanges on May 18, 2026, as required under SEBI's updated master circular HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026. The key details of the resignation are summarised below:

Parameter:	Details
Name of Director:	Mrs. Pallavi Dinodia Gupta
DIN:	06566637
Designation:	Independent Director
Effective Date of Resignation:	May 18, 2026
Reason for Resignation:	Personal and professional reasons

Impact on Board Committees

Consequent to her resignation, Mrs. Pallavi Dinodia Gupta will also cease to hold her positions across multiple board-level committees of Jagsonpal Pharmaceuticals. The committee roles she will vacate are as follows:

Audit Committee: Member
Corporate Social Responsibility Committee: Member
Stakeholders Relationship Committee: Chairperson

Directorships in Other Listed Entities

As part of the mandatory disclosure under Regulation 30, the company also provided details of Mrs. Gupta's directorships and committee memberships in other listed entities at the time of her resignation:

Listed Entity:	Category of Directorship	Committee Memberships
IndiaMART InterMESH Limited:	Independent Director	Member – Audit Committee, Stakeholder Relationship Committee, Corporate Social Responsibility & Sustainability Committee; Chairman – Nomination & Remuneration Committee, Committee of Independent Directors
Voith Paper Fabrics India Limited:	Independent Director	Member – Nomination & Remuneration Committee; Chairperson – Audit Committee
Lumax Industries Limited:	Independent Director	Member – Audit Committee, Corporate Social Responsibility Committee

Reasons Cited by the Resigning Director

In her resignation letter addressed to the Board of Directors of Jagsonpal Pharmaceuticals Limited, Mrs. Pallavi Dinodia Gupta cited increasing professional commitments, certain personal engagements, and health considerations as the primary reasons for her decision. She stated that these factors constrained her ability to devote the requisite time and attention to effectively discharge her duties and responsibilities as an Independent Director to the standards she considered appropriate.

Mrs. Gupta confirmed that there are no other material reasons for her resignation beyond those stated in her resignation letter, in compliance with applicable regulatory requirements. The company's Company Secretary and Compliance Officer, Pratham Rawal, signed and submitted the regulatory filing on May 18, 2026.